Search results for "Intensive Care Medicine"

showing 10 items of 2228 documents

What have we learnt 50 years after the first Fontan procedure?

2020

The Fontan procedure is often the only definitive palliative surgical option for patients with a variety of complex CHD sharing in common, a single, dominant ventricle. In recent decades, imaging and therapeutic improvement have played a crucial role in those patients in whom many complications can hamper their life. After 50 years from the first procedure, heart transplantation remains the only definitive treatment for those with a failing Fontan circulation.

medicine.medical_specialtymedicine.medical_treatmentHeart VentriclesMEDLINEFontan ProcedureHistory 21st CenturyUniventricular HeartFontan circulationFontan procedureRisk FactorsMedicineHumansVentricular FunctionTreatment Failurecardiovascular diseasesIntensive care medicineHeart transplantationbusiness.industryHemodynamicsGeneral MedicineRecovery of FunctionHistory 20th CenturyHeart TransplantationDiffusion of InnovationCardiology and Cardiovascular MedicinebusinessFontan total cavopulmonary connection univentricular heart
researchProduct

Prevention of early complications and late consequences after acute pulmonary embolism: Focus on reperfusion techniques

2017

Pulmonary embolism (PE) is a major cause of acute cardiovascular mortality and long-term morbidity. Right ventricular (RV) dysfunction is the key determinant of prognosis in the acute phase of PE, and residual RV dysfunction is associated with the development of post-PE functional impairment, chronic thromboembolic disease, and higher costs of treatment over the long term. Patients with clinically overt RV failure, i.e. hemodynamic collapse at presentation (high-risk PE), necessitate immediate thrombolytic treatment to relieve the obstruction in the pulmonary circulation; surgical or catheter-directed removal of the thrombus can be an alternative option. For patients with a high risk of ble…

medicine.medical_specialtymedicine.medical_treatmentHemodynamics030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansThrombolytic TherapyThromboembolic diseaseDecompensation030212 general & internal medicineThrombusIntensive care medicineCardiovascular mortalitybusiness.industryHematologyHeparinThrombolysisPrognosismedicine.diseasePulmonary embolismTreatment OutcomeAcute DiseaseReperfusionCardiologyPulmonary Embolismbusinessmedicine.drugThrombosis Research
researchProduct

The diagnosis of and treatment recommendations for anxiety disorders.

2014

Anxiety disorders (panic disorder/agoraphobia, generalized anxiety disorder, social phobia, and specific phobias) are the most common mental illnesses. For example, the 12-month prevalence of panic disorder/agoraphobia is 6%.This guideline is based on controlled trials of psychotherapy and pharmacotherapy, retrieved by a systematic search for original articles that were published up to 1 July 2013. Experts from 20 specialty societies and other organizations evaluated the evidence for each treatment option from all available randomized clinical trials and from a synthesis of the recommendations of already existing international and German guidelines.403 randomized controlled trials were eval…

medicine.medical_specialtymedicine.medical_treatmentMEDLINElaw.invention03 medical and health sciences0302 clinical medicinePharmacotherapyRandomized controlled triallawRisk FactorsmedicineHumansIntensive care medicinePsychiatryPsychodynamic psychotherapyPsychotropic Drugsbusiness.industryGeneral MedicineGuidelineClinical Practice GuidelineAnxiety Disorders030227 psychiatry3. Good healthCognitive behavioral therapyPsychotherapyNeurologyPractice Guidelines as TopicAnxietymedicine.symptomReuptake inhibitorbusiness030217 neurology & neurosurgeryDeutsches Arzteblatt international
researchProduct

Proposal for a preventive protocol for medication-related osteonecrosis of the jaw.

2021

Background Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse reaction experienced by some patients exposed to certain drugs (antiresorptives such as bisphosphonates or denosumab, and antiangiogenic drugs). From a review of the literature it appears that there is no uniform criterion when selecting preventive measures; these vary according to author. Likewise, the measures recommended are usually general, so that in few cases they result in specific actions to be applied depending on the different variables involved such as the type of drug used, the duration of its application, the underlying pathology, the presence or absence of risk factors, etc. The aim of this stud…

medicine.medical_specialtymedicine.medical_treatmentOsteoporosisMEDLINEReviewsleep disturbancesolder people03 medical and health sciences0302 clinical medicinemedicineHumansIntensive care medicineAdverse effectDental implantGeneral DentistryUNESCO:CIENCIAS MÉDICASProtocol (science)dental implantOral Medicine and PathologyedentulismBone Density Conservation AgentsDiphosphonatesbusiness.industryOsteonecrosis030206 dentistrymedicine.diseaseDenosumabSystematic reviewOtorhinolaryngologyOsteoporosisSurgeryBisphosphonate-Associated Osteonecrosis of the JawbusinessOsteonecrosis of the jawmedicine.drug
researchProduct

Managing Persistent Hypoxemia: what is new?

2017

Mechanical ventilation is the standard life-support technique for patients with severe acute respiratory failure. However, some patients develop persistent and refractory hypoxemia because their lungs are so severely damaged that they are unable to respond to the application of high inspired oxygen concentration and high levels of positive end-expiratory pressure. In this article, we review current knowledge on managing persistent hypoxemia in patients with injured lungs.

medicine.medical_specialtymedicine.medical_treatmentPhysiologyReviewmechanical ventilationGeneral Biochemistry Genetics and Molecular BiologyHypoxemia03 medical and health sciences0302 clinical medicineRefractorysevere acute respiratory failuremedicineAcute respiratory failureIn patientGeneral Pharmacology Toxicology and PharmaceuticsIntensive care medicineMechanical ventilationInspired oxygen concentrationhypoxemiaGeneral Immunology and Microbiologypersistent hypoxemiabusiness.industry030208 emergency & critical care medicineGeneral MedicineArticlesrespiratory tract diseases030228 respiratory systemRespiratory Problems in Critical Caremedicine.symptombusinessF1000Research
researchProduct

The EHA research roadmap

2021

International audience; In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research(1) aiming to highlight achievements in the diagnostics and treatment of blood disorders, and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1-2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including 11 sections, each of which will be published…

medicine.medical_specialtymedicine.medical_treatmentPlatelet disorderClinical scienceHematopoietic stem cell transplantation030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicinemedicineDiseases of the blood and blood-forming organsIntensive care medicine030304 developmental biology0303 health sciencesHematologybusiness.industryTransfusion medicineHematologyHemostatic Disorders3. Good healthBlood DisorderEuropean policy[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologiePerspective[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieRC633-647.5businessHemaSphere
researchProduct

Chronic kidney disease and dyslipidaemia

2016

Chronic kidney disease (CKD) has to be considered as a high, or even very high risk cardiovascular risk condition, since it leads to an increase in cardiovascular mortality that continues to increase as the disease progresses. An early diagnosis of CKD is required, together with an adequate identification of the risk factors, in order to slow down its progression to more severe states, prevent complications, and to delay, whenever possible, the need for renal replacement therapy. Dyslipidaemia is a factor of the progression of CKD that increases the risk in developing atherosclerosis and its complications. Its proper control contributes to reducing the elevated cardiovascular morbidity and …

medicine.medical_specialtymedicine.medical_treatmentRenal functionDisease030204 cardiovascular system & hematologyurologic and male genital diseases03 medical and health sciences0302 clinical medicineRisk FactorsmedicineHumans030212 general & internal medicineRenal replacement therapyRenal Insufficiency ChronicIntensive care medicineDyslipidemiasGeneral Environmental ScienceCardiovascular mortalitybusiness.industryAnticholesteremic AgentsGeneral EngineeringCholesterol LDLmedicine.diseaseRenal Replacement TherapyCardiovascular DiseasesRenal transplantDisease ProgressionPhysical therapyGeneral Earth and Planetary SciencesHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessVery high riskDyslipidemiaKidney diseaseClínica e Investigación en Arteriosclerosis (English Edition)
researchProduct

Outpatient Treatment of Hemorrhoidal Disease: The Alternative Way to Treat Hemorrhoidal Disease in a Simple, Safe and Effective Manner.

2021

Background:: Hemorrhoidal disease is a widespread problem in healthy working patients. The traditional surgical approaches cause a loss of several working days related to the post-- operative course that is often painful. To avoid these problems while offering a symptoms resolution in patients with low degrees hemorrhoids, the non-surgical treatments are nowadays largely proposed in proctological clinics. Methods: We resume the recent literature on the issue to offer a practical and easy to use guide for clinicians. Results: Rubber band ligation, injection sclerotherapy and infrared coagulation are cost effective, safe and effective treatments for patients with II- and III-degree hemorrhoi…

medicine.medical_specialtymedicine.medical_treatmentReviewInfrared coagulationRubber band ligationHemorrhoidsHemorrhoid ligationHemorroid infrared coagulationHemorrhoidal diseaseHemorrhoidsInjection sclerotherapyOutpatientsSclerotherapymedicineHumansIn patientIntensive care medicineLigationPharmacologySurgical approachbusiness.industryGeneral Medicinemedicine.diseaseHemorroid complicationTreatment OutcomeDisease cureOutpatient treatmentQuality of LifeHemorrhoid sclerotherapybusinessReviews on recent clinical trials
researchProduct

The long and winding road of non steroidal antinflammatory drugs and paracetamol in cancer pain management: A critical review

2013

The aim of this review was to assess the value of NSAIDs and paracetamol in patients with cancer pain to update a previous review performed ten years ago on this topic. The approach was analytic and based on clinical considerations, rather than on raw evidence, which often does not provide useful information in clinical practice. Both published reports from an extensive search of electronic data bases were collected from January 2001 to December 2011. A free-text search method was used including the following words and their combination: “Anti-inflammatory drugs OR paracetamol OR acetaminophen” AND/OR “cancer pain”. Any randomized-controlled trial was considered. Thirteen reports fulfitted …

medicine.medical_specialtymedicine.medical_treatmentSettore MED/41 - AnestesiologiaPainlaw.inventionPain ladderRandomized controlled triallawNeoplasmsmedicineHumansPain ManagementCancer painIntensive care medicineAcetaminophenbusiness.industryPatient-controlled analgesiaAnti-Inflammatory Agents Non-SteroidalanalgesiaHematologyAnalgesics Non-NarcoticAcetaminophenKetorolacParacetamolTreatment OutcomeOncologyOpioidAnesthesiaElectronic dataAnti-inflammatory drugCancer painbusinessCancer pain; Anti-inflammatory drugs; Paracetamol; analgesiamedicine.drugCritical Reviews in Oncology/Hematology
researchProduct

Thrombolytic therapy for submassive pulmonary embolism.

2012

Approximately 10% of all patients with acute pulmonary embolism (PE) die within the first three months after diagnosis. However, PE is not universally life-threatening, but covers a wide spectrum of clinical severity and death risk. Thrombolytic treatment is indicated patients with acute massive PE who are at high risk for early death, i.e. those patients who present with arterial hypotension and shock. On the other hand, low molecular-weight heparin or fondaparinux is adequate treatment for most normotensive patients with PE. Recombinant tissue plasminogen activator, given as 100 mg infusion over 2 h, is the treatment of choice for patients with PE, although older regimens using urokinase …

medicine.medical_specialtymedicine.medical_treatmentStreptokinaseVentricular Dysfunction RightClinical Biochemistry030204 cardiovascular system & hematologyFondaparinuxlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialFibrinolytic AgentslawPolysaccharidesRisk FactorsInternal medicinemedicineHumansStreptokinaseThrombolytic Therapy030212 general & internal medicineIntensive care medicineUrokinaseClinical Trials as Topicbusiness.industryHeparinThrombolysisHeparin Low-Molecular-Weightmedicine.diseaseUrokinase-Type Plasminogen ActivatorTroponin3. Good healthPulmonary embolismRadiographyOncologyFondaparinuxTissue Plasminogen ActivatorAcute DiseaseCardiologybusinessPulmonary EmbolismBiomarkersmedicine.drugCohort studyBest practiceresearch. Clinical haematology
researchProduct